Abcam, ab109196, Anti-Sumo 2 + Sumo 3 + Sumo 4 antibody [EPR300(2)]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal Sumo 4 antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR300(2),
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Storage information-Stable for 12 months at -20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SUMO proteins known as small ubiquitin-like modifiers play key roles in post-translational modification of proteins. SUMO2 SUMO3 and SUMO4 are members of the SUMO family sharing about 87% identity in their amino acid sequences. The average molecular mass of SUMO2 and SUMO3 is approximately 11 kDa while SUMO4 is slightly larger. These proteins are widely expressed in eukaryotic cells and are primarily found in the nucleus where they conjugate with target proteins to modify their stability localization and interaction with other proteins.
Biological function summary
SUMO protein family modifies target proteins and influences important cellular processes like transcriptional regulation DNA repair and cell cycle progression. SUMO2 and SUMO3 unlike SUMO1 often form poly-SUMO chains which interact with other ubiquitin-like modifiers and create multi-protein complexes. SUMO4 lacks the processing enzymes necessary for maturation suggesting a different role or regulation. These processes facilitate the dynamic response of the cell to various physiological and stress signals which is critical to maintaining normal cellular functions.
Pathways
SUMO conjugation regulates numerous signaling pathways including the p53 and NF-kB pathways. In the p53 pathway SUMO modification helps control the stability and activity of the p53 protein a major tumor suppressor that monitors DNA damage and apoptosis. In the NF-kB pathway SUMOylation impacts the transcriptional activity of NF-kB subunits by modifying proteins like IκBα and influencing the inflammatory response. The interaction with existing molecular players in these pathways enables precise control of gene expression and cellular responses to internal and external stimuli.
Altered SUMOylation links to cancer and neurodegenerative diseases. In several cancers disruptions in SUMO2 and SUMO3 conjugation affect the regulation of oncogenic and tumor suppressor pathways modifying cell proliferation apoptosis and metastasis. Regarding neurodegenerative diseases SUMO3 may influence processes like protein aggregation and neuronal apoptosis notable in diseases like Alzheimer's where it interacts with Tau protein. Together these findings suggest that abnormal SUMO modification contributes significantly to the development and progression of these diverse pathologies.